CAR-T technology was first studied for cancer therapy research. Immunotherapy has become a revolution in the field of cancer treatment. Compared with traditional methods such as radiation and chemotherapy, immunotherapy is more specific with less ity. CAR-T cell therapy is the most promising method among various kinds of immunotherapies, which has shown the ability to eliminate various tumors, especially for B cell malignancies, with a remission rate of up to 95%.
CAR T-cell therapy is an immunotherapy that uses genetically engineered T cells to target cancer cells. It is to extract T cells from the blood of the patient (or other people), and then they are genetically engineered to express chimeric antigen receptors (CARs) on their surfaces. hen these CAR-T cells with recognition function are re-injected into the patient’s body, they can recognize and attack cancer cells in the human body, thereby achieving the effect of killing cancer.
“Currently, there are two FDA-approved CAR-T cell therapies, Novartis’ for the treatment of acute lymphoblastic leukemia and Gilead’s Yescarta for the treatment of large B-cell lymphoma.” as introduced by a scientist from Creative Biolabs, a biotech company focusing on CAR-T therapy development services.
And now, CAR-T technology also shows its glamour in diseases caused by aging. Cell senescence refers to a state of cell cycle arrest, in which proliferating cells will be resistant to growth-promoting stimuli and will not continue to proliferate. Cell senescence is On the one hand, it can prevent the replication of cells containing damaged DNA and play an important anti-tumor function. On the other hand, it can cause many related diseases, such as cancer, tissue degeneration and inflammatory diseases. Finding a safe way to clear senescent cells will be a major breakthrough in the treatment of these diseases.
